PDB code,Name,Last commit,Last update,Pdb title,Method,Resolution,Residue number,Unnamed: 8,State,State_comments,Corresponding article,Evidence,Fusion
2R4R,2R4R_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human beta2 adrenoceptor,X-RAY DIFFRACTION,"3,4",796,2007-11-06,inactive,"Isn't clear, r b2AR365‚ÄìFab5","10.1038/nature06325, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517684/","Currently, there are several crystal structures of both active and inactive β2AR. In all, six inactive crystal structures (PDB codes: 2RH1, 2R4R, 3D4S, 3KJ6, 3NY8, 3NYA) a",0
2R4S,2R4S_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human beta2 adrenoceptor,X-RAY DIFFRACTION,"3,4",773,2007-11-06,inactive,"Isn't clear, b2AR24/365‚ÄìFab5","10.1038/nature06325, https://books.google.ru/books?id=2NQkDwAAQBAJ&pg=PA35&lpg=PA35&dq=2r4s+pdb+inactive&source=bl&ots=DmdLQxuAAY&sig=ACfU3U0Mf5DAz9pxYG4BTglXW0K4VpgeDA&hl=ru&sa=X&ved=2ahUKEwj6gfjF5fDtAhVqiYsKHe06AvY4ChDoATAHegQICRAC#v=onepage&q=2r4s%20pdb%20inactive&f=false",,0
2RH1,2RH1_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,High resolution crystal structure of human B2-adrenergic G protein-coupled receptor.,X-RAY DIFFRACTION,"2,4",500,2007-10-30,Inactive,Inactive,"doi: 10.1073/pnas.1519626112, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/",in book,0
2VT4,2VT4_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL,X-RAY DIFFRACTION,"2,7",1252,2008-06-24,Inactive,"Inactive, b1AR-m23",10.1038/nature07101,"mutant receptor was preferentially in the antagonist (R) state, DOI: 10.1073/pnas.0711253105",0
2Y00,2Y00_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB92),X-RAY DIFFRACTION,"2,5",630,2011-01-12,inactive,"Active(?), agonist binding, number of contacts","10.1038/nature09746, https://books.google.ru/books?id=2NQkDwAAQBAJ&pg=PA35&lpg=PA35&dq=2r4s+pdb+inactive&source=bl&ots=DmdLQxuAAY&sig=ACfU3U0Mf5DAz9pxYG4BTglXW0K4VpgeDA&hl=ru&sa=X&ved=2ahUKEwj6gfjF5fDtAhVqiYsKHe06AvY4ChDoATAHegQICRAC#v=onepage&q=2r4s%20pdb%20inactive&f=false",,0
2Y01,2Y01_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB102),X-RAY DIFFRACTION,"2,6",630,2011-03-30,Inactive,Inactive,doi:10.1038/nature09746,,0
2Y02,2Y02_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST CARMOTEROL,X-RAY DIFFRACTION,"2,6",630,2011-01-12,Inactive,Inactive,doi:10.1038/nature09746,,0
2Y03,2Y03_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST ISOPRENALINE,X-RAY DIFFRACTION,"2,85",630,2011-01-12,Inactive,Inactive,doi:10.1038/nature09746,,0
2Y04,2Y04_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST SALBUTAMOL,X-RAY DIFFRACTION,"3,05",630,2011-01-12,Inactive,Inactive,doi:10.1038/nature09746,,0
2YCW,2YCW_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CARAZOLOL,X-RAY DIFFRACTION,3,626,2011-06-01,Inactive,Inactive,10.1073/pnas.1100185108,,0
2YCX,2YCX_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL,X-RAY DIFFRACTION,"3,25",626,2011-06-01,Inactive,Inactive,10.1073/pnas.1100185108,,0
2YCY,2YCY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL,X-RAY DIFFRACTION,"3,15",626,2011-06-08,Inactive,Inactive,10.1073/pnas.1100185108,,T4-Lysozyme
2YCZ,2YCZ_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST IODOCYANOPINDOLOL,X-RAY DIFFRACTION,"3,65",626,2011-06-01,Inactive,Inactive,10.1073/pnas.1100185108,,0
2YDO,2YDO_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised HUMAN A2a Receptor with adenosine bound,X-RAY DIFFRACTION,3,325,2011-05-18,intermediate,intermediate,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146096/,"Co-crystallisation with agonist adenosine,  These data all suggest that A2AR-GL31 is in an intermediate conformation between R and R*, which is consistent with the structural analysis presented below.(c)",0
2YDV,2YDV_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised HUMAN A2a Receptor with NECA bound,X-RAY DIFFRACTION,"2,6",325,2011-05-18,intermediate,intermediate,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146096/,"Co-crystallisation with synthetic agonist NECA, The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G protein binding site.(c)",0
3D4S,3D4S_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Cholesterol bound form of human beta2 adrenergic receptor.,X-RAY DIFFRACTION,"2,8",490,2008-06-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2601552/,"Co-crystallisation with cholesterol and the partial inverse agonist timolol, https://books.google.ru/books?id=ql3FBAAAQBAJ&pg=PA50&lpg=PA50&dq=3D4S+inactive&source=bl&ots=pBbbdRtStG&sig=ACfU3U2hGlS9mfTQrfmmpzzTVs9cQabmOg&hl=ru&sa=X&ved=2ahUKEwj0pdHerMDqAhVIXpoKHSgxB_kQ6AEwAHoECAYQAQ#v=onepage&q=3D4S%20inactive&f=false",0
3EML,3EML_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The 2.6 A Crystal Structure of a Human A2A Adenosine Receptor bound to ZM241385.,X-RAY DIFFRACTION,"2,6",488,2008-10-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586971/,Co-crystallisation with ZM241385,0
3KJ6,3KJ6_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of a Methylated beta2 Adrenergic Receptor-Fab complex,X-RAY DIFFRACTION,"3,4",797,2010-02-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805469/,"Methylated receptor co-crystallyzed with Fab5,  We observed no significant changes between the crystal structure of a methylated-β2AR/Fab complex bound to carazolol and that of the non-methylated receptor (Supplementary Fig. 5 and Supplementary Table 2)., Moreover, these studies provide new insight into the dynamic behavior of GPCRs not addressable by static, inactive-state crystal structures.(c)",T4-Lysozyme
3NY8,3NY8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,"Crystal structure of the human beta2 adrenergic receptor in complex with the inverse agonist ICI 118,551",X-RAY DIFFRACTION,"2,84",490,2010-08-11,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923663/,"All three structures show the same overall fold observed for the previous Carβ2AR-t4l and Timβ2AR-t4l structures with a rmsd of ~0.3Å (over β2AR Cα atoms only) between all five reported β2AR-t4l-ligand structures, https://books.google.ru/books?id=nuaYDwAAQBAJ&pg=PA74&lpg=PA74&dq=3NY9+inactive&source=bl&ots=HEOshc_LgI&sig=ACfU3U0BzdyNsKJqVRbNtrfVM8QfSamw-A&hl=ru&sa=X&ved=2ahUKEwikrarSscDqAhVxwMQBHWfODuQQ6AEwAHoECAoQAQ#v=onepage&q=3NY9%20inactive&f=false(c)",T4-Lysozyme
3NY9,3NY9_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human beta2 adrenergic receptor in complex with a novel inverse agonist,X-RAY DIFFRACTION,"2,84",490,2010-08-11,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923663/,"All three structures show the same overall fold observed for the previous Carβ2AR-t4l and Timβ2AR-t4l structures with a rmsd of ~0.3Å (over β2AR Cα atoms only) between all five reported β2AR-t4l-ligand structures, https://books.google.ru/books?id=nuaYDwAAQBAJ&pg=PA74&lpg=PA74&dq=3NY9+inactive&source=bl&ots=HEOshc_LgI&sig=ACfU3U0BzdyNsKJqVRbNtrfVM8QfSamw-A&hl=ru&sa=X&ved=2ahUKEwikrarSscDqAhVxwMQBHWfODuQQ6AEwAHoECAoQAQ#v=onepage&q=3NY9%20inactive&f=false(c)",T4-Lysozyme
3NYA,3NYA_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human beta2 adrenergic receptor in complex with the neutral antagonist alprenolol,X-RAY DIFFRACTION,"3,16",490,2010-08-11,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923663/,"All three structures show the same overall fold observed for the previous Carβ2AR-t4l and Timβ2AR-t4l structures with a rmsd of ~0.3Å (over β2AR Cα atoms only) between all five reported β2AR-t4l-ligand structures, https://books.google.ru/books?id=nuaYDwAAQBAJ&pg=PA74&lpg=PA74&dq=3NY9+inactive&source=bl&ots=HEOshc_LgI&sig=ACfU3U0BzdyNsKJqVRbNtrfVM8QfSamw-A&hl=ru&sa=X&ved=2ahUKEwikrarSscDqAhVxwMQBHWfODuQQ6AEwAHoECAoQAQ#v=onepage&q=3NY9%20inactive&f=false(c)",T4-Lysozyme
3ODU,3ODU_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The 2.5 A structure of the CXCR4 chemokine receptor in complex with small molecule antagonist IT1t,X-RAY DIFFRACTION,"2,5",1004,2010-10-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074590/#SD1,Calcium flux assay,T4-Lysozyme
3OE0,3OE0_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the CXCR4 chemokine receptor in complex with a cyclic peptide antagonist CVX15,X-RAY DIFFRACTION,"2,9",515,2010-10-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074590/#SD2,Calcium flux assay,T4-Lysozyme
3OE6,3OE6_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the CXCR4 chemokine receptor in complex with a small molecule antagonist IT1t in I222 spacegroup,X-RAY DIFFRACTION,"3,2",508,2010-10-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074590/#SD3,Calcium flux assay,T4-Lysozyme
3OE8,3OE8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the CXCR4 chemokine receptor in complex with a small molecule antagonist IT1t in P1 spacegroup,X-RAY DIFFRACTION,"3,1",1506,2010-10-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074590/#SD4,Calcium flux assay,T4-Lysozyme
3OE9,3OE9_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the chemokine CXCR4 receptor in complex with a small molecule antagonist IT1t in P1 spacegroup,X-RAY DIFFRACTION,"3,1",998,2010-10-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074590/#SD5,Calcium flux assay,T4-Lysozyme
3P0G,3P0G_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of a nanobody-stabilized active state of the beta2 adrenoceptor,X-RAY DIFFRACTION,"3,5",627,2011-01-19,Active,Active,doi:10.1038/nature09648.,,0
3PBL,3PBL_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human dopamine D3 receptor in complex with eticlopride,X-RAY DIFFRACTION,"2,89",962,2010-11-03,Inactive,Inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058422/,Co-crystallisation with antagonist(A common feature thought to be important in many class A GPCRs is the ionic lock - a salt bridge between the charged Arg3.50 in the conserved “D[E]RY” motif and Asp/Glu6.30 at the cytoplasmic side of helices III and VI. This interaction is observed in all of the inactive rhodopsin crystal structures (Fig. 2A) (26–27) and has been implicated through mutagenesis as a major factor in stabilizing the receptors in the inactive conformation (28–29).),T4-Lysozyme
3PDS,3PDS_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Irreversible Agonist-Beta2 Adrenoceptor Complex,X-RAY DIFFRACTION,"3,5",458,2011-01-12,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074335/,"even an agonist with zero dissociation inefficiently stabilizes an active conformation of the β2AR in a lipid bilayer environment, consistent with a higher stability of the inactive carazolol-bound conformation.(c)",0
3PWH,3PWH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised Adenosine A2A Receptor,X-RAY DIFFRACTION,"3,3",329,2011-09-07,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/21885291,"Thermostabilized with inactive-state inducing muattions(containing the stabilising mutations A54L2.52, T88A3.36,K122A4.43, V239A6.4)",
3QAK,3QAK_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Agonist bound structure of the human adenosine A2a receptor,X-RAY DIFFRACTION,"2,71",488,2011-03-09,active_or_active_like,active(active-like(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399762/pdf/nihms378544.pdf)),active-like(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399762/pdf/nihms378544.pdf),,0
3REY,3REY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised adenosine A2A receptor in complex with XAC,X-RAY DIFFRACTION,"3,31",329,2011-09-07,inactive,inactive,"Thermostabilized with inactive-state inducing muattions(containing the stabilising mutations A54L2.52, T88A3.36,K122A4.43, V239A6.4), XAC  were found to equally inhibit constitutive
activity",,0
3RFM,3RFM_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised adenosine A2A receptor in complex with caffeine,X-RAY DIFFRACTION,"3,6",329,2011-09-07,inactive,inactive,"Thermostabilized with inactive-state inducing muattions(containing the stabilising mutations A54L2.52, T88A3.36,K122A4.43, V239A6.4), caffeine were found to equally inhibit constitutive
activity",,0
3RZE,3RZE_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human histamine H1 receptor in complex with doxepin,X-RAY DIFFRACTION,"3,1",452,2011-06-15,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/,Co-crystallisation with first-generation H1R-antagonist,T4-Lysozyme
3SN6,3SN6_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the beta2 adrenergic receptor-Gs protein complex,X-RAY DIFFRACTION,"3,2",1451,2011-07-20,Active,Active,doi: 10.1073/pnas.1519626112,Active complex with agonist and G-protein,0
3UON,3UON_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist,X-RAY DIFFRACTION,3,467,2012-02-01,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345277/ , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/",co-crystallisation with antagonist R-(−)-3-QNB,0
3UZA,3UZA_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,"Thermostabilised Adenosine A2A receptor in complex with 6-(2,6-Dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine",X-RAY DIFFRACTION,"3,27",329,2012-03-21,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308197/ , https://opm.phar.umich.edu/proteins/1940","Co-crystallisation with antagonist 4g, ",BRIL
3UZC,3UZC_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,"Thermostabilised Adenosine A2A receptor in complex with 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol",X-RAY DIFFRACTION,"3,34",329,2012-03-21,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308197/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736361/table/T1/",Co-crystallisation with antagonist 4e,0
3V2W,3V2W_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of a Lipid G protein-Coupled Receptor at 3.35A,X-RAY DIFFRACTION,"3,35",520,2012-02-15,inactive,inactive?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338336/,"Co-crystallisation with antagonist sphingolipid mimic, https://books.google.ru/books?id=CUmQDwAAQBAJ&pg=PA16&lpg=PA16&dq=3V2W+state&source=bl&ots=6D2Rp_gSR5&sig=ACfU3U25922lJviF_zMC4kBWgLi6_uivJQ&hl=ru&sa=X&ved=2ahUKEwim5NSKo8DqAhW9zcQBHZ_dCTs4ChDoATADegQICRAB#v=onepage&q=3V2W%20state&f=false",T4-Lysozyme
3V2Y,3V2Y_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of a Lipid G protein-Coupled Receptor at 2.80A,X-RAY DIFFRACTION,"2,8",520,2012-02-15,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338336/",,T4-Lysozyme
3VG9,3VG9_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human adenosine A2A receptor with an allosteric inverse-agonist antibody at 2.7 A resolution,X-RAY DIFFRACTION,"2,7",766,2012-02-01,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303121/,"Co-crystallisation with an allosteric inverse-agonist antibody,  CDR-H3 is located in a similar position to the G-protein C-terminal fragment in the active opsin structure1 and to the CDR-3 of the nanobody in the active β2 adrenergic receptor structure2 but locks the A2AAR in an inactive conformation.(c)",T4-Lysozyme
3VGA,3VGA_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human adenosine A2A receptor with an allosteric inverse-agonist antibody at 3.1 A resolution,X-RAY DIFFRACTION,"3,1",766,2012-02-01,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303121/,"Co-crystallisation with an allosteric inverse-agonist antibody,  CDR-H3 is located in a similar position to the G-protein C-terminal fragment in the active opsin structure1 and to the CDR-3 of the nanobody in the active β2 adrenergic receptor structure2 but locks the A2AAR in an inactive conformation.(c)",0
3VW7,3VW7_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human protease-activated receptor 1 (PAR1) bound with antagonist vorapaxar at 2.2 angstrom,X-RAY DIFFRACTION,"2,2",484,2012-12-12,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/,Co-crystallisation with antagonist vorapaxar,0
3ZEV,3ZEV_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of Thermostable Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion,X-RAY DIFFRACTION,3,692,2014-01-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926081/,"Co-crystallisation without lizozyme, Our structures are fully consistent with all biochemically defined ligand-contacting residues, and they represent an inactive NTR1 state at the cytosolic side.(c)",0
3ZPQ,3ZPQ_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised turkey beta1 adrenergic receptor with 4-(piperazin-1- yl)-1H-indole bound (compound 19),X-RAY DIFFRACTION,"2,8",630,2013-04-03,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654563/, https://www.cell.com/cms/10.1016/j.bpj.2019.03.025/attachment/2985bc18-8d47-4011-95e9-c1317eee3609/mmc1","Co-crystallisation with with 4-(piperazin-1- yl)-1H-indole bound (compound 19), These observations suggest that both of the fragments are antagonists, although data to support this hypothesis have not yet been generated. However, the interactions of the phenyl substituent headgroup with Ser2115.42 on H5 differ between the two fragment molecules, as only 19 can form a hydrogen bond to Ser2115.42. In the β1AR-20 structure, the conformation of Ser2115.42 is similar to that observed in the β1AR-carazolol structure (Figure ​(Figure5b5b and Figure ​Figure5d),5d), whereas in the β1AR-19 structure the conformation of Ser2115.42 corresponds to that observed in the β1AR-cyanopindolol structure (Figure ​(Figure5a5a and Figure ​Figure5c).5c).(c)",0
3ZPR,3ZPR_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised turkey beta1 adrenergic receptor with 4-methyl-2-(piperazin-1-yl) quinoline bound,X-RAY DIFFRACTION,"2,7",630,2013-04-03,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654563/, https://www.cell.com/cms/10.1016/j.bpj.2019.03.025/attachment/2985bc18-8d47-4011-95e9-c1317eee3609/mmc1","Co-crystallisation with 4-methyl-2-(piperazin-1-yl) quinoline bound, These observations suggest that both of the fragments are antagonists, although data to support this hypothesis have not yet been generated. However, the interactions of the phenyl substituent headgroup with Ser2115.42 on H5 differ between the two fragment molecules, as only 19 can form a hydrogen bond to Ser2115.42. In the β1AR-20 structure, the conformation of Ser2115.42 is similar to that observed in the β1AR-carazolol structure (Figure ​(Figure5b5b and Figure ​Figure5d),5d), whereas in the β1AR-19 structure the conformation of Ser2115.42 corresponds to that observed in the β1AR-cyanopindolol structure (Figure ​(Figure5a5a and Figure ​Figure5c).5c).(c)",BRIL
4AMI,4AMI_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist bucindolol,X-RAY DIFFRACTION,"3,2",630,2012-05-23,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384003/,"Co-crystallisation with biased agonist (antagonist) bucindolol, RMSD of Cα positions <0.5 Å) to the inactive state structure of β1AR (2VT4).",BRIL
4AMJ,4AMJ_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist carvedilol,X-RAY DIFFRACTION,"2,3",630,2012-05-23,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384003/,"Co-crystallisation with biased agonist (antagonist) carvedilol, RMSD of Cα positions <0.5 Å) to the inactive state structure of β1AR (2VT4).",0
4BUO,4BUO_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,High Resolution Structure of Thermostable Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion,X-RAY DIFFRACTION,"2,75",690,2014-01-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926081/,"Co-crystallisation without lizozyme,  Our structures are fully consistent with all biochemically defined ligand-contacting residues, and they represent an inactive NTR1 state at the cytosolic side.(c)",BRIL
4BV0,4BV0_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,High Resolution Structure of Evolved Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion,X-RAY DIFFRACTION,"3,1",696,2014-01-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926081/,"Co-crystallisation without lizozyme,  Our structures are fully consistent with all biochemically defined ligand-contacting residues, and they represent an inactive NTR1 state at the cytosolic side.(c)",0
4BVN,4BVN_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Ultra-thermostable beta1-adrenoceptor with cyanopindolol bound,X-RAY DIFFRACTION,"2,1",315,2014-04-02,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963952/,"Co-crystallisation with weak partial agonist cyanopindolol, The structure of β1AR-JM50 was determined to 2.1 Å resolution using diffraction data collected from a single cryo-cooled crystal (see Table 1 for crystallographic data). The overall structure is virtually identical to the 2.7 Å resolution structure of cyanopindolol-bound β36-m23 (c)",BRIL
4BWB,4BWB_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of Evolved Agonist-bound Neurotensin Receptor 1 Mutant without Lysozyme Fusion,X-RAY DIFFRACTION,"3,57",696,2014-01-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926081/,"Co-crystallisation with agonist, Our structures are fully consistent with all biochemically defined ligand-contacting residues, and they represent an inactive NTR1 state at the cytosolic side.(c)",0
4DAJ,4DAJ_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the M3 Muscarinic Acetylcholine Receptor,X-RAY DIFFRACTION,"3,4",1916,2012-02-22,inactive,inactive,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529910/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/",co-crystallisation with antagonist Tiotropium,T4-Lysozyme
4DJH,4DJH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human kappa opioid receptor in complex with JDTic,X-RAY DIFFRACTION,"2,9",960,2012-03-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/,Co-crystallisation with selective antagonist JDTic,0
4DKL,4DKL_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the mu-opioid receptor bound to a morphinan antagonist,X-RAY DIFFRACTION,"2,8",464,2012-03-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/,Co-crystallisation with morphinan antagonist,T4-Lysozyme
4EA3,4EA3_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the N/OFQ Opioid Receptor in Complex with a Peptide Mimetic,X-RAY DIFFRACTION,"3,01",868,2012-04-25,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/,"Co-crystallisation with peptide mimetic antagonist Banyu Compound-24, ",T4-Lysozyme
4EIY,4EIY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the chimeric protein of A2aAR-BRIL in complex with ZM241385 at 1.8A resolution,X-RAY DIFFRACTION,"1,8",447,2012-07-25,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399762/pdf/nihms378544.pdf,co-crystallisation with antagonist zm241385[as 3EML],T4-Lysozyme
4EJ4,4EJ4_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the delta opioid receptor bound to naltrindole,X-RAY DIFFRACTION,"3,4",461,2012-05-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523198/,"Co-crystallisation with  subtype-selective antagonist naltrindole, With the structure of the δ-OR, all classical opioid receptors have now been crystallized and solved in inactive conformations.(c)",0
4GBR,4GBR_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Receptor,X-RAY DIFFRACTION,"3,99",472,2012-10-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464249/,"Co-crystallisation with inserted T4-lyzozyme, However, in the T4L-β2AR-Δ-ICL3 structure ICL2 is not involved in packing interactions, yet is an extended loop that is nearly identical to that observed in the other inactive state β2AR structures (Fig. 6). Thus, this extended loop structure may reflect an inactive state.(c)",T4-Lysozyme
4GPO,4GPO_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Oligomeic Turkey Beta1-Adrenergic G Protein-Coupled Receptor,X-RAY DIFFRACTION,"3,5",626,2013-02-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618578/,"Crystallisation in ligand-free form, Structural comparisons show that this ligand-free state is in an inactive conformation(c)",Soluble cytochrome b562
4GRV,4GRV_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,The crystal structure of the neurotensin receptor NTS1 in complex with neurotensin (8-13),X-RAY DIFFRACTION,"2,8",516,2012-10-17,inactive_or_active-like,"inactive, active-like???","https://www.ncbi.nlm.nih.gov/pubmed/30706767, https://www.ncbi.nlm.nih.gov/pubmed/23051748",fail in promoting nucleotide exchange in G protein,T4-Lysozyme
4IAQ,4IAQ_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine (PSI Community Target),X-RAY DIFFRACTION,"2,8",403,2013-03-13,active_or_active-like,active?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644373/,"Co-crystallisation with full agonist dihydroergotamine, Due to the high similarity between these two structures (figure S2), for brevity we focus on the structure of the 5-HT1B-1/ERG complex for analysis and discussion of key structural features for ligand recognition and selectivity in 5-HT1B versus 5-HT2B receptors, As shown in the accompanying paper, these differences in ERG interactions correlate with different functional states: at the 5-HT1B receptor ERG causes full activation; whereas ERG induces intermediate G protein activation and β-arrestin biased signaling at the 5-HT2B recepto(c)",BRIL
4IAR,4IAR_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PSI Community Target),X-RAY DIFFRACTION,"2,7",401,2013-03-13,active_or_active-like,active?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644373/,"Co-crystallisation with full agonist ergotamine, As shown in the accompanying paper, these differences in ERG interactions correlate with different functional states: at the 5-HT1B receptor ERG causes full activation; whereas ERG induces intermediate G protein activation and β-arrestin biased signaling at the 5-HT2B recepto(c)",0
4IB4,4IB4_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the chimeric protein of 5-HT2B-BRIL in complex with ergotamine,X-RAY DIFFRACTION,"2,7",430,2013-03-13,active_or_active-like,"active, active-like?",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644390/,"Co-crystallisation with full agonist ergotamine, Our analysis indicates that the 5-HT1B/ERG structure has most of the attributes of a classical agonist-induced active-like state, consistent with our biochemical findings that ERG is a comparatively unbiased agonist at the 5-HT1B receptor.(c)",BRIL
4LDE,4LDE_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of beta2 adrenoceptor bound to BI167107 and an engineered nanobody,X-RAY DIFFRACTION,"2,79",589,2013-09-25,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822040/#SD1,"Co-crystallisation with agonist BI167107 and active state-stabilizing nanobody,  The water-mediated hydrogen bond between Tyr2195.58 and Tyr3267.53 is possible only in the active conformation of the receptor (c)",T4-Lysozyme
4LDL,4LDL_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of beta2 adrenoceptor bound to hydroxybenzylisoproterenol and an engineered nanobody,X-RAY DIFFRACTION,"3,1",589,2013-09-25,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822040/#SD1,"Co-crystallisation with agonist hydroxybenzylisoproterenol and active state-stabilizing nanobody, The water-mediated hydrogen bond between Tyr2195.58 and Tyr3267.53 is possible only in the active conformation of the receptor (c)",T4-Lysozyme
4LDO,4LDO_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of beta2 adrenoceptor bound to adrenaline and an engineered nanobody,X-RAY DIFFRACTION,"3,2",589,2013-09-25,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822040/#SD1,"Co-crystallisation with agonist adrenaline and active state-stabilizing nanobody, The water-mediated hydrogen bond between Tyr2195.58 and Tyr3267.53 is possible only in the active conformation of the receptor (c)",0
4MBS,4MBS_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of the CCR5 Chemokine Receptor,X-RAY DIFFRACTION,"2,71",828,2013-09-11,inactive,"inactive,(+)",https://www.ncbi.nlm.nih.gov/pubmed/?term=30234300,Co-crystallisation with antagonist(maraviroc),T4-Lysozyme
4MQS,4MQS_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of active human M2 muscarinic acetylcholine receptor bound to the agonist iperoxo,X-RAY DIFFRACTION,"3,5",476,2013-11-27,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020789/,agonist co-crystallisation,0
4MQT,4MQT_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of active human M2 muscarinic acetylcholine receptor bound to the agonist iperoxo and allosteric modulator LY2119620,X-RAY DIFFRACTION,"3,7",476,2013-11-27,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020789/,agonist+allosteric modulator co-crystallisation,BRIL
4N6H,4N6H_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,1.8 A Structure of the human delta opioid 7TM receptor (PSI Community Target),X-RAY DIFFRACTION,"1,8",414,2013-12-25,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931418/,"Co-crystallisation with.., As a whole, the cluster comprising the sodium ion and eight water molecules mediates extensive intra-helical hydrogen bond networks between helices I, II, III, VI and VII in the core of the receptor, when it is stabilized in an inactive state conformation(c)",BRIL
4NC3,4NC3_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the 5-HT2B receptor solved using serial femtosecond crystallography in lipidic cubic phase.,X-RAY DIFFRACTION,"2,8",430,2013-12-18,active_or_active-like,"active, active-like?",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902108/,"Co-crystallisation with agonist ergotamine, Otherwise, the receptor domains of the 5-HT2B-XFEL and 5-HT2B-SYN structures are very similar (receptor Cα root mean square deviation (rmsd) = 0.45 Å, excluding flexible residues at the N-terminus, 48–51, and in the extracellular loop (ECL) 2, 195–205) (Fig. 2). The ligand ergotamine has indistinguishable electron density and placement (total ligand rmsd = 0.32 Å) ",BRIL
4NTJ,4NTJ_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human P2Y12 receptor in complex with an antithrombotic drug,X-RAY DIFFRACTION,"2,62",466,2014-03-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174307/,"Co-crystallisation with non-nucleotide reversible antagonist AZD1283, The helix VI intracellular tip is shifted slightly outward, and the whole helix VI is translated along its axis towards the intracellular surface by a half α-helical turn as compared with other known GPCR structures (Fig. 1d and Extended Data Fig. 4d). Owing to this shift, the conserved R1223.50 in the D(E)R3.50Y motif, which forms an ionic or a hydrogen-bonding lock with E6.30 or T6.34 in rhodopsin and several other GPCRs, is actually located at the same level as a hydrophobic side-chain V2386.37 in the P2Y12R structure (c)",0
4PHU,4PHU_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of Human GPR40 bound to allosteric agonist TAK-875,X-RAY DIFFRACTION,"2,33",491,2014-07-16,inactive-like,inactive-like,https://www.ncbi.nlm.nih.gov/pubmed/?term=25043059,"Allosteric binding of a partial agonist TAK-875, On the basis of a Ca21 flux assay, a
construct with the four point mutations and native ICL3 revealed
reduced potency by more than 1000-fold compared with the wild-type(c)",BRIL
4PXZ,4PXZ_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of P2Y12 receptor in complex with 2MeSADP,X-RAY DIFFRACTION,"2,5",466,2014-04-30,active-like,active-like?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128917/,"Co-crystallisation with full agonist MeSADP,  Only minor changes in helices VI and VII were observed in the intracellular part of P2Y12R-2MeSADP. They do not appear consistent, however, with large changes in helical positions observed in the intracellular region in active state agonist-bound A2AAR, or β2AR stabilized by G-protein12,14. It is therefore likely that the P2Y12R-2MeSADP structure represents an “agonist-bound inactive state” with respect to the intracellular region, similar to the one observed in agonist-bound β1AR and β2AR without G-protein or a G-protein mimic stabilizing their active state(c)",BRIL
4PY0,4PY0_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of P2Y12 receptor in complex with 2MeSATP,X-RAY DIFFRACTION,"3,1",466,2014-04-30,active_or_active-like,"active, active-like(?)",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128917/,"Co-crystallisation with full agonist MeSATP,  Only minor changes in helices VI and VII were observed in the intracellular part of P2Y12R-2MeSADP. They do not appear consistent, however, with large changes in helical positions observed in the intracellular region in active state agonist-bound A2AAR, or β2AR stabilized by G-protein12,14. It is therefore likely that the P2Y12R-2MeSADP structure represents an “agonist-bound inactive state” with respect to the intracellular region, similar to the one observed in agonist-bound β1AR and β2AR without G-protein or a G-protein mimic stabilizing their active state(c)",T4-Lysozyme
4QKX,4QKX_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of beta2 adrenoceptor bound to a covalent agonist and an engineered nanobody,X-RAY DIFFRACTION,"3,3",589,2014-07-23,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115510/,"Co-crystallisation with covalently bound agonist and active-state stabilizing nanobody, Nb6B9 mimics the G protein by binding at the intracellular surface of the β2AR, and thus stabilizes the active state of the receptor(c)",0
4RWA,4RWA_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Synchrotron structure of the human delta opioid receptor in complex with a bifunctional peptide (PSI community target),X-RAY DIFFRACTION,"3,28",832,2015-01-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351130/,"Co-crystallisation with bi-functional δ-OR antagonist and μ-OR agonist tetrapeptide DIPP-NH2, Overall, the inactive state δ-OR – DIPP-NH2 structure is similar to the previously determined 1.8 Å resolution structure of δ-OR bound to the morphinan derivative naltrindole(c)",T4-Lysozyme
4RWD,4RWD_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL structure of the human delta opioid receptor in complex with a bifunctional peptide,X-RAY DIFFRACTION,"2,7",832,2015-01-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351130/,"Co-crystallisation with bi-functional δ-OR antagonist and μ-OR agonist tetrapeptide DIPP-NH2, Overall, the inactive state δ-OR – DIPP-NH2 structure is similar to the previously determined 1.8 Å resolution structure of δ-OR bound to the morphinan derivative naltrindole(c)",BRIL
4RWS,4RWS_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of CXCR4 and viral chemokine antagonist vMIP-II complex (PSI Community Target),X-RAY DIFFRACTION,"3,1",578,2015-02-11,inactive,inactive?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362693/,"Co-crystallisation with viral antagonist vMIP-II, Here we report the crystal structure of the chemokine receptor CXCR4 in complex with the viral chemokine antagonist vMIP-II at 3.1 Å resolution., However, because docking was performed with an inactive receptor conformation, further structural studies will be necessary to fully understand activation mechanisms(c)",0
4S0V,4S0V_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human OX2 orexin receptor bound to the insomnia drug Suvorexant,X-RAY DIFFRACTION,"2,5",559,2015-01-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/25533960,"Co-crystallisation with antagonist(Overall, numerous hydrophobic and polar contacts bind TM5 and TM6
to the other TM domains, restricting the outward movement of these
a-helices necessary for GPCR activation. The suvorexant-bound hOX2R
structure thus represents an inactive-state conformation, consistent
with the efficacy profile of suvorexant as a DORA ligand.)",BRIL
4U14,4U14_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the M3 muscarinic acetylcholine receptor bound to the antagonist tiotropium crystallized with disulfide-stabilized T4 lysozyme (dsT4L),X-RAY DIFFRACTION,"3,57",460,2014-11-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408211/#SD1,"Co-crystallisation with antagonist tiotropium and disulfide-stabilized T4 lysozyme (dsT4L), The structure of M3 in the three crystals is nearly identical (RMSD = 0.44 comparing M3-T4L and M3-dsT4L, RMSD = 0.63 comparing M3-T4L and M3-mT4L)(c)",Glycogen synthase
4U15,4U15_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,M3-mT4L receptor bound to tiotropium,X-RAY DIFFRACTION,"2,8",836,2014-11-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408211/#SD1,"Co-crystallisation with antagonist tiotropium, The structure of M3 in the three crystals is nearly identical (RMSD = 0.44 comparing M3-T4L and M3-dsT4L, RMSD = 0.63 comparing M3-T4L and M3-mT4L)(c)",T4-Lysozyme
4U16,4U16_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,M3-mT4L receptor bound to NMS,X-RAY DIFFRACTION,"3,7",836,2014-11-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408211/#SD1,"Co-crystallisation with antagonist NMS, The structure of M3 in the three crystals is nearly identical (RMSD = 0.44 comparing M3-T4L and M3-dsT4L, RMSD = 0.63 comparing M3-T4L and M3-mT4L)(c)",T4-Lysozyme
4UG2,4UG2_b_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised HUMAN A2a Receptor with CGS21680 bound,X-RAY DIFFRACTION,"2,6",650,2015-04-08,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720118/,"Co-crystallisation with agonist CGS 21680, orthrombic form, This conformation of the receptor is best described as “active-like” (Lebon et al., 2011b). The major internal rearrangements of side chains and α-helices characteristic of agonist binding are observed in the receptor core within all of these structures, but the opening of the cytoplasmic face to allow G protein coupling has not occurred to the same extent as observed in the β2-adrenergic receptor bound to a heterotrimeric G protein(c)",BRIL
4UHR,4UHR_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Thermostabilised HUMAN A2a Receptor with CGS21680 bound,X-RAY DIFFRACTION,"2,6",325,2015-04-08,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720118/,"Co-crystallisation with agonist CGS 21680, monoclynic form, This conformation of the receptor is best described as “active-like” (Lebon et al., 2011b). The major internal rearrangements of side chains and α-helices characteristic of agonist binding are observed in the receptor core within all of these structures, but the opening of the cytoplasmic face to allow G protein coupling has not occurred to the same extent as observed in the β2-adrenergic receptor bound to a heterotrimeric G protein(c)",0
4XEE,4XEE_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structure of active-like neurotensin receptor,X-RAY DIFFRACTION,"2,9",547,2015-07-29,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515772/,,0
4XES,4XES_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structure of active-like neurotensin receptor,X-RAY DIFFRACTION,"2,6",547,2015-07-29,intermediate_or_active-like,"intermediate, active-like",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515772/,NTSR1-LF mediates moderate nucleotide exchange at Gαq,T4-Lysozyme
4XNV,4XNV_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,The human P2Y1 receptor in complex with BPTU,X-RAY DIFFRACTION,"2,2",421,2015-04-01,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408927/,"Co-crystallisation with antagonist MRS2500, Although MRS2500 and BPTU bind to distinct sites in P2Y1R, these two ligands stabilize the receptor in similar inactive conformations(c)",Rubredoxin
4XNW,4XNW_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,The human P2Y1 receptor in complex with MRS2500,X-RAY DIFFRACTION,"2,7",842,2015-04-01,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408927/,"Co-crystallisation with antagonist BPTU, Although MRS2500 and BPTU bind to distinct sites in P2Y1R, these two ligands stabilize the receptor in similar inactive conformations(c)",0
4XT1,4XT1_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of a nanobody-bound viral GPCR bound to human chemokine CX3CL1,X-RAY DIFFRACTION,"2,89",587,2015-03-04,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445376/,Co-crystallisation with CX3CL1 and nanobody Nb7,Rubredoxin
4XT3,4XT3_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of a viral GPCR bound to human chemokine CX3CL1,X-RAY DIFFRACTION,"3,8",453,2015-03-04,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445376/,"Co-crystallisation with CX3CL1, We find that both the nanobody-bound and -free US28-CX3CL1 complexes bear the structural hallmarks of an active state(c)",0
4YAY,4YAY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL structure of human Angiotensin Receptor,X-RAY DIFFRACTION,"2,9",414,2015-04-22,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427029/,"Co-crystallisation with selective antagonist ZD7155, Based on previous observations that mutations of either Asn1113.35 or Asn2957.46 induce constitutive activation of the receptor, it was proposed that the inactive conformation of AT1R is stabilized by interactions between Asn1113.35 and Asn2957.46. Further, it was suggested that binding of AngII to the wild-type (WT) receptor disrupts the hydrogen bonds between Asn1113.35 and Asn2957.46, thus allowing Asn2957.46 to interact with the conserved Asp742.50 (Balakumar and Jagadeesh, 2014; Unal and Karnik, 2014). Indeed, two intramolecular hydrogen bonds are observed between Asn1113.35 and Asn2957.46 in the AT1R-ZD7155 structure (Figure 6A)(c)",BRIL
4Z34,4Z34_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO9780307,X-RAY DIFFRACTION,3,464,2015-06-03,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476059/,"Co-crystallisation with antagonist ONO9780307, The main fold of the antagonist bound LPA1 receptor is similar to other inactive class A GPCRs, with a canonical seven-transmembrane α-helical bundle",BRIL
4Z35,4Z35_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-9910539,X-RAY DIFFRACTION,"2,9",464,2015-06-03,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476059/,"Co-crystallisation with antagonist ONO9910539, The main fold of the antagonist bound LPA1 receptor is similar to other inactive class A GPCRs, with a canonical seven-transmembrane α-helical bundle",0
4Z36,4Z36_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-3080573,X-RAY DIFFRACTION,"2,9",459,2015-06-03,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476059/,"Co-crystallisation with antagonist ONO3080573, The main fold of the antagonist bound LPA1 receptor is similar to other inactive class A GPCRs, with a canonical seven-transmembrane α-helical bundle",BRIL
4ZJ8,4ZJ8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structures of the human OX1 orexin receptor bound to selective and dual antagonists,X-RAY DIFFRACTION,"2,75",553,2016-03-09,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=26950369,Co-crystallisation with antagonist,0
4ZJC,4ZJC_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structures of the human OX1 orexin receptor bound to selective and dual antagonists,X-RAY DIFFRACTION,"2,83",553,2016-03-09,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=26950369,Co-crystallisation with antagonist,Endolysin
4ZUD,4ZUD_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of Human Angiotensin Receptor in Complex with Inverse Agonist Olmesartan at 2.8A resolution.,X-RAY DIFFRACTION,"2,8",410,2015-10-07,inactive,inactive?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705918/,"Co crystallisation with Inverse Agonist Olmesartan, Meanwhile, a sodium ion was implicated in the allosteric stabilization of an inactive conformation in many class A GPCRs (37). Therefore, a combination of the N1113.35A mutation effect with the absence of a sodium ion and its corresponding allosteric modulation may result in a dramatically increased AngII binding affinity. However, further studies are needed to fully understand the mechanism for the allosteric modulation of AT1R by sodium ion.(c)",BRIL
5A8E,5A8E_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound,X-RAY DIFFRACTION,"2,4",315,2015-09-30,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658595/,Co-crystallisation with inverce agonist 7-methylcyanopindolol,BRIL
5C1M,5C1M_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of active mu-opioid receptor bound to the agonist BU72,X-RAY DIFFRACTION,"2,1",421,2015-08-05,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639397/,"Co-crystallisation with agonist BU72 and active-state stabilizing nanobody 39, In the active μOR structure, the morphinan scaffold of BU72 adopts a pose that is sterically incompatible with the inactive position of TM3(c)",T4-Lysozyme
5CXV,5CXV_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human M1 muscarinic acetylcholine receptor bound to antagonist Tiotropium,X-RAY DIFFRACTION,"2,7",522,2016-03-09,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915387/,inverse agonist co-crystallisation,T4-Lysozyme
5D5A,5D5A_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,In meso in situ serial X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K,X-RAY DIFFRACTION,"2,48",500,2016-01-13,inactive,inactive?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756617/,Co-crystallisation with inverse agonist carazolol,T4-Lysozyme
5D5B,5D5B_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,In meso X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K,X-RAY DIFFRACTION,"3,8",500,2016-01-13,inactive,inactive?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756617/,Co-crystallisation with inverse agonist carazolol,0
5D6L,5D6L_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,beta2AR-T4L - CIM,X-RAY DIFFRACTION,"3,2",500,2016-08-17,inactive,inactive?,https://sci-hub.tw/10.1038/nprot.2017.057,Co-crystallisation with inverse agonist carazolol,Endolysin
5DHG,5DHG_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with C-35 (PSI Community Target),X-RAY DIFFRACTION,3,848,2015-10-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670589/,Co-crystallisation with antagonist C35,0
5DHH,5DHH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with SB-612111 (PSI Community Target),X-RAY DIFFRACTION,3,848,2015-10-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670589/,"Co-crystallisation with antagonist SB612111, While the multiplicity of ligand binding modes stunts crystallization of inactive-state (antagonist-bound) receptors, this degeneracy is further amplified in the presence of agonists by virtue of multiple active-state conformations(c)",BRIL
5DSG,5DSG_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the M4 muscarinic acetylcholine receptor (M4-mT4L) bound to tiotropium,X-RAY DIFFRACTION,"2,6",844,2016-03-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915387/,"inverse agonist co-crystallisation, While the multiplicity of ligand binding modes stunts crystallization of inactive-state (antagonist-bound) receptors, this degeneracy is further amplified in the presence of agonists by virtue of multiple active-state conformations(c)",T4-Lysozyme
5F8U,5F8U_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Ligand occupancy in crystal structure of beta1-adrenergic receptor previously submitted by Huang et al,X-RAY DIFFRACTION,"3,35",626,2015-12-23,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806846/,"Co-crystallisation in ligand free-state, structural comparisons show that this ligand-free state is in an inactive conformation(c)",T4-Lysozyme
5G53,5G53_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the adenosine A2A receptor bound to an engineered G protein,X-RAY DIFFRACTION,"3,4",1086,2016-08-03,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979997/,"Co-crystallisation with agonist and mini-Gs protein, t is striking that the structural change from the inactive conformation to the active-intermediate state5 is characterised by the concerted rotation of H5, H6 and H7, whereas the conformation change from the active-intermediate state to the active conformation upon mini-Gs binding is characterised by the bending of H6 with little further rotation(c)",0
5GLH,5GLH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Human endothelin receptor type-B in complex with ET-1,X-RAY DIFFRACTION,"2,8",519,2016-09-07,inactive_or_active-like,"inactive, partly active state?",https://sci-hub.tw/10.1038/nature19319,"Co-crystallisation with agonist ET1, However, the cytoplasmic segment of TM6 is tilted towards
the inside of the receptor and packed against the surrounding TM helices, where it probably adopts an inactive conformation (Extended Data
Fig. 9a). In addition, the conserved E/DRY motif forms an intrahelical
salt bridge between Asp1983.49 and Arg1993.50, which is the structural
hallmark of an inactive GPCR(c)",BRIL
5GLI,5GLI_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Human endothelin receptor type-B in the ligand-free form,X-RAY DIFFRACTION,"2,5",464,2016-09-07,inactive,inactive,https://sci-hub.tw/10.1038/nature19319,Ligand-free form most likely to be inactive cause ionic loc isn't collapsed,0
5IU4,5IU4_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with ZM241385 at 1.7A resolution,X-RAY DIFFRACTION,"1,72",433,2016-06-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=27312113,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,BRIL
5IU7,5IU7_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12c at 1.9A resolution,X-RAY DIFFRACTION,"1,9",433,2016-06-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=27312113,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,BRIL
5IU8,5IU8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12f at 2.0A resolution,X-RAY DIFFRACTION,2,433,2016-06-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=27312113,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,BRIL
5IUA,5IUA_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12b at 2.2A resolution,X-RAY DIFFRACTION,"2,2",433,2016-06-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=27312113,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,T4-Lysozyme
5IUB,5IUB_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12x at 2.1A resolution,X-RAY DIFFRACTION,"2,1",433,2016-06-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=27312113,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,BRIL
5JQH,5JQH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,"Structure of beta2 adrenoceptor bound to carazolol and inactive-state stabilizing nanobody, Nb60",X-RAY DIFFRACTION,"3,2",1192,2016-07-13,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961583/,"Co-crystallisation with antagonist and inactive-state stabilizing nanobody, We show that Nb60 stabilizes a previously unappreciated low affinity receptor state which corresponds to one of two inactive receptor conformations as delineated by X-ray crystallography and NMR spectroscopy(c)",BRIL
5JTB,5JTB_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the chimeric protein of A2aAR-BRIL with bound iodide ions,X-RAY DIFFRACTION,"2,8",447,2017-05-31,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429034/,Co-crystallisation with antagonist ZM241385,Endolysin
5K2A,5K2A_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,2.5 angstrom A2a adenosine receptor structure with sulfur SAD phasing using XFEL data,X-RAY DIFFRACTION,"2,5",447,2016-09-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035125/,co-crystallisation with antagonist zm241385 [as 4EIY],BRIL
5K2B,5K2B_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,2.5 angstrom A2a adenosine receptor structure with MR phasing using XFEL data,X-RAY DIFFRACTION,"2,5",447,2016-09-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035125/,co-crystallisation with antagonist zm241385 [as 4EIY],Flavodoxin
5K2C,5K2C_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,1.9 angstrom A2a adenosine receptor structure with sulfur SAD phasing and phase extension using XFEL data,X-RAY DIFFRACTION,"1,9",447,2016-09-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035125/,co-crystallisation with antagonist zm241385 [as 4EIY],BRIL
5K2D,5K2D_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,1.9A angstrom A2a adenosine receptor structure with MR phasing using XFEL data,X-RAY DIFFRACTION,"1,9",447,2016-09-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035125/,co-crystallisation with antagonist zm241385 [as 4EIY],BRIL
5KW2,5KW2_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,The extra-helical binding site of GPR40 and the structural basis for allosteric agonism and incretin stimulation,X-RAY DIFFRACTION,"2,76",491,2018-05-02,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917010/,"Co-crystallisation with synthetic full agonist, This GPR40 receptor has a T4 lysozyme (T4L) protein inserted into the third intracellular loop (ICL3), as well as four point mutations that increase expression and thermal stability. These modifications likely constrain GPR40 in an inactive conformation, which could explain the reduced relative binding of [3H]-AM-1638 to the stabilized receptor vs. wild type(c)",TrxA
5LWE,5LWE_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human CC chemokine receptor type 9 (CCR9) in complex with vercirnon,X-RAY DIFFRACTION,"2,8",662,2016-12-07,inactive,inactive,https://sci-hub.tw/10.1038/nature20606,"Co-crystallisation with antagonist  vercirnon,  These modifications did
not alter vercirnon binding properties of the receptor compared with
wild-type (Extended Data Fig. 3); however, stabilization with the [3
H]
vercirnon antagonist precludes G-protein coupling of the final StaR(c)",T4-Lysozyme
5MZJ,5MZJ_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with theophylline at 2.0A resolution,X-RAY DIFFRACTION,2,434,2017-07-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28712806,"The ionic lock between R1053.50 of the D[E]RY motif and E2296.30, which stabilizes the inactive conformation of class A GPCRs, is maintained in A1R, also mutations A2A-StaR2-bRIL",BRIL
5MZP,5MZP_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with caffeine at 2.1A resolution,X-RAY DIFFRACTION,"2,1",433,2017-07-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28712806,"The ionic lock between R1053.50 of the D[E]RY motif and E2296.30, which stabilizes the inactive conformation of class A GPCRs, is maintained in A1R, also mutations A2A-StaR2-bRIL",0
5N2R,5N2R_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with PSB36 at 2.8A resolution,X-RAY DIFFRACTION,"2,8",433,2017-07-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28712806,"The ionic lock between R1053.50 of the D[E]RY motif and E2296.30, which stabilizes the inactive conformation of class A GPCRs, is maintained in A1R, also mutations A2A-StaR2-bRIL",0
5N2S,5N2S_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution,X-RAY DIFFRACTION,"3,3",436,2017-07-26,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28712806,"The ionic lock between R1053.50 of the D[E]RY motif and E2296.30, which stabilizes the inactive conformation of class A GPCRs, is maintained in A1R, also mutations A2A-StaR2-bRIL",BRIL
5NDD,5NDD_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ8838 at 2.8 angstrom resolution,X-RAY DIFFRACTION,"2,8",619,2017-05-03,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28445455,"CO-crystallisation with stabilizing mutations and antagonist AZ8838 (Ca flux assay and arrestin recruitment assay)  AZ8838 is hydrogen-bonded to the carboxylate of Asp228ECL2
and this may directly alter agonist binding, or the compound may
mediate its action allosterically by stabilizing an inactive state of the
receptor to prevent agonist activation.(c)",BRIL  Fab3949
5NDZ,5NDZ_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ3451 at 3.6 angstrom resolution,X-RAY DIFFRACTION,"3,6",619,2017-05-03,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28445455,"Co-crystallisation with antagonist AZ3451, structure is within RMSD of 0,21 A of 5NDD",0
5NJ6,5NJ6_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in ternary complex with Fab3949 and AZ7188 at 4.0 angstrom resolution,X-RAY DIFFRACTION,4,869,2017-05-03,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28445455,Co-crystallisation with weak antagonist AZ7188 and inactive-state stabilizing antibody,T4-Lysozyme  BRIL
5NLX,5NLX_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,A2A Adenosine receptor room-temperature structure determined by serial millisecond crystallography,X-RAY DIFFRACTION,"2,14",433,2017-09-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599499/,"Co-crystallisation with antagonist ZM241385, ",BRIL
5NM2,5NM2_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,A2A Adenosine receptor cryo structure,X-RAY DIFFRACTION,"1,95",433,2017-09-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599499/,"Co-crystallisation with antagonist ZM241385, ",Soluble cytochrome b562
5NM4,5NM4_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,A2A Adenosine receptor room-temperature structure determined by serial femtosecond crystallography,X-RAY DIFFRACTION,"1,7",433,2017-09-27,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599499/,"Co-crystallisation with antagonist ZM241385, ",BRIL
5O9H,5O9H_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of thermostabilised human C5a anaphylatoxin chemotactic receptor 1 (C5aR) in complex with NDT9513727,X-RAY DIFFRACTION,"2,7",634,2018-01-10,inactive,inactive,https://sci-hub.tw/10.1038/nature25025,"Co-crystallisation with antagonist antagonist NDT9513727, The overall structure of C5aR1 is similar to that of other class A
receptors crystallized in the inactive state and consists of the canonical seven-transmembrane (TM1–TM7) helix arrangement (c) NDT9513727 seems to antagonize receptor activation from outside
the helical bundle by stabilizing a network of interactions that hold the
receptor in the inactive state and by inhibiting the helical movements
required to transition to the agonist conformation for downstream signalling(c)",Soluble cytochrome b562
5OLG,5OLG_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-ZM241385 complex at 1.86A obtained from in meso soaking experiments.,X-RAY DIFFRACTION,"1,87",434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5OLH,5OLH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-Vipadenant complex at 2.6A obtained from in meso soaking experiments.,X-RAY DIFFRACTION,"2,6",434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5OLO,5OLO_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-Tozadenant complex at 3.1A obtained from in meso soaking experiments.,X-RAY DIFFRACTION,"3,1",434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5OLV,5OLV_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-LUAA47070 complex at 2.0A obtained from in meso soaking experiments.,X-RAY DIFFRACTION,2,434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5OLZ,5OLZ_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.9A obtained from bespoke co-crystallisation experiments.,X-RAY DIFFRACTION,"1,9",434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5OM1,5OM1_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 2.1A obtained from in meso soaking experiments (1 hour soak).,X-RAY DIFFRACTION,"2,1",434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5OM4,5OM4_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.86A obtained from in meso soaking experiments (24 hour soak).,X-RAY DIFFRACTION,2,434,2018-01-17,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29311713,Thermostabilasing mutations locking rec in inactive states (A2A-StaR2-bRIL) + various inverse agonists and antagonists,Soluble cytochrome b562
5T04,5T04_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,STRUCTURE OF CONSTITUTIVELY ACTIVE NEUROTENSIN RECEPTOR,X-RAY DIFFRACTION,"3,3",519,2016-12-21,active-intermediate,active-intermediate,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141500/,Constitutively active structure of ,BRIL
5T1A,5T1A_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists,X-RAY DIFFRACTION,"2,81",508,2016-12-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159191/,"Co-crystallisatiom with antagonist(Along with the stability and equilibrium binding data, these results further corroborate the hypothesis that BMS-681 and CCR2-RA-[R] cooperatively stabilize a preferred inactive conformation of CCR2-T4L.)",T4-Lysozyme
5TGZ,5TGZ_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of the Human Cannabinoid Receptor CB1,X-RAY DIFFRACTION,"2,8",452,2016-11-02,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322940/,Co-crystallisation with antagonist. Although the crystal structure we present is in the inactive state(c),Glycogen synthase
5TUD,5TUD_d_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structural Insights into the Extracellular Recognition of the Human Serotonin 2B Receptor by an Antibody,X-RAY DIFFRACTION,3,1812,2017-07-26,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547598/,"Co-crystallisation with antibody fragment bound to the extracellular side of rec, The 5-HT2B receptor is captured in a well-defined active-like state, most likely stabilized by the crystal lattice.(c) ",Endolysin
5TVN,5TVN_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the LSD-bound 5-HT2B receptor,X-RAY DIFFRACTION,"2,9",402,2017-02-01,inactive_or_active-like,???,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289311/,,BRIL
5TZR,5TZR_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,GPR40 in complex with partial agonist MK-8666,X-RAY DIFFRACTION,"2,2",491,2017-06-07,inactive-like,inactive-like,https://www.ncbi.nlm.nih.gov/pubmed/?term=28581512,"Co-crystallisation with partial agonist MK-8666, The binary and ternary complex
structures presented here are consistent with the previously reported
GPR40 structure with TAK875 (ref. 6), and with structures of other
agonist-bound GPCRs lacking downstream effectors, in that the intracellular portion of the receptors are observed in an ‘inactive-like’ state
with regard to TM6 positioning(c)",0
5TZY,5TZY_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,GPR40 in complex with AgoPAM AP8 and partial agonist MK-8666,X-RAY DIFFRACTION,"3,22",491,2017-06-07,inactive-like,inactive-like,https://www.ncbi.nlm.nih.gov/pubmed/?term=28581512,"Co-crystallisation with partial agonist MK-8666 and agonist AgoPAM AP8, The binary and ternary complex
structures presented here are consistent with the previously reported
GPR40 structure with TAK875 (ref. 6), and with structures of other
agonist-bound GPCRs lacking downstream effectors, in that the intracellular portion of the receptors are observed in an ‘inactive-like’ state
with regard to TM6 positioning(c)",Endolysin
5U09,5U09_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,High-resolution crystal structure of the human CB1 cannabinoid receptor,X-RAY DIFFRACTION,"2,6",508,2016-12-07,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433929/,"Co-crystallisation with inverce agonist, We incorporated the point mutation T210A, which was previously shown to stabilize the inactive conformation of CB1 and increase thermostability. By analogy to other rhodopsin family (class A) GPCRs18, the taranabant-bound CB1 structure represents an inactive conformation with respect to G protein binding, with a canonical ionic lock formed between R2143.50 and D3386.30 .",0
5UEN,5UEN_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human adenosine A1 receptor A1AR-bRIL in complex with the covalent antagonist DU172 at 3.2A resolution,X-RAY DIFFRACTION,"3,2",832,2017-03-01,inactive,inactive,https://sci-hub.tw/10.1016/j.cell.2017.01.042,"Co-crystallisation with covalent antagonist DU172, Overall, the structure of the A1-AR is typical of other Class A
GPCRs crystallized in an inactive conformation (Figures 2A and
2C) with a partially formed ‘‘ionic lock’’ (Figure S4) that constrains
GPCRs in an inactive state and may thus explain why the A1-AR
displays relatively low constitutive activity(c)",0
5UIG,5UIG_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of adenosine A2A receptor bound to a novel triazole-carboximidamide antagonist,X-RAY DIFFRACTION,"3,5",444,2017-02-08,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338372/,"Co-crystallisation with antagonist ZM241385, ur structure represents an inactive state structure of the receptor based on the conformation of TM6, and conserved motifs such as E/DRY and NPXXY are virtually identical to that in A2AR–BRIL–ZM241385 structure (8)(c)",BRIL
5UIW,5UIW_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of CC Chemokine Receptor 5 (CCR5) in complex with high potency HIV entry inhibitor 5P7-CCL5,X-RAY DIFFRACTION,"2,2",486,2017-06-28,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572563/,"Inaccuracies are to be expected in the CCR5-CCL5 model because of the exclusion, for practical reasons, of water molecules at the bottom of the binding pocket, as well as the use of fixed positions of the receptor helices in an inactive state structure.(+ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422131/ )",Flavodoxin
5UNF,5UNF_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,"XFEL structure of human angiotensin II type 2 receptor (Monoclinic form) in complex with compound 1 (N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl])",X-RAY DIFFRACTION,"2,8",822,2017-04-05,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525545/,"While the previously determined AT1R structures captured the receptor in a classical inactive state, all three AT2R structures, obtained in this work, display an active-like conformation",BRIL
5UNG,5UNG_b_Active_loop_optimized_reg.pdb,added structures,1 week ago,"XFEL structure of human angiotensin II type 2 receptor (Orthorhombic form) in complex with compound 1 (N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl] methyl}-3,4-dihydroquinazolin-6-yl)thiophene-2-carboxamide)",X-RAY DIFFRACTION,"2,8",411,2017-04-05,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525545/,"While the previously determined AT1R structures captured the receptor in a classical inactive state, all three AT2R structures, obtained in this work, display an active-like conformation",BRIL
5UNH,5UNH_b_Active_loop_optimized_reg.pdb,added structures,1 week ago,"Synchrotron structure of human angiotensin II type 2 receptor in complex with compound 2 (N-[(furan-2-yl)methyl]-N-(4-oxo-2-propyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl}-3,4-dihydroquinazolin-6-yl)benzamide)",X-RAY DIFFRACTION,"2,9",822,2017-04-05,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525545/,"While the previously determined AT1R structures captured the receptor in a classical inactive state, all three AT2R structures, obtained in this work, display an active-like conformation",T4-Lysozyme  BRIL
5UVI,5UVI_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron Radiation,X-RAY DIFFRACTION,"3,2",447,2017-05-24,inactive,inactive,https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5571807&blobtype=pdf,Co-crystallisation with antagonist ZM241385,Rubredoxin
5V54,5V54_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of 5-HT1B receptor in complex with methiothepin,X-RAY DIFFRACTION,"3,9",790,2018-02-07,intermediate,intermediate?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847559/,"Co-crystallisation with inverse agonist methiothepin, The 5-HT1BR/MT structure represents an intermediate state between active and inactive conformations.Thus the 5-HT1BR/MT structure with the OB1 fusion may represent an intermediate state that is prone to transition to an inactive conformation, but is locked by the OB1 fusion.(c)",Soluble cytochrome b562
5VBL,5VBL_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of apelin receptor in complex with agonist peptide,X-RAY DIFFRACTION,"2,6",424,2017-05-31,inactive,inactive,https://sci-hub.tw/10.1016/j.str.2017.04.008,"Co-crystallisation with apelin mimetic peptide agonist, Model-based mutations V117A and W261K were further introduced to stabilize APJR at the inactive state for conformational homogeneity(c)",BRIL
5VRA,5VRA_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,2.35-Angstrom In situ Mylar structure of human A2A adenosine receptor at 100 K,X-RAY DIFFRACTION,"2,35",447,2017-12-13,inactive,inactive?,https://sci-hub.tw/10.1038/nprot.2017.135,Co-crystallisation with antagonist ZM241385,Endolysin
5WB1,5WB1_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Ligand-free US28 with stabilizing intracellular nanobody,X-RAY DIFFRACTION,"3,51",458,2018-06-13,active_or_active_like,active?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993540/,"Co-crystallisation with active-state stabilizing nanobody, This confirms that the nanobody does not deform US28 but merely selects a subset of pre-existing, stable, active-like conformations.(c)",0
5WB2,5WB2_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,US28 bound to engineered chemokine CX3CL1.35 and nanobodies,X-RAY DIFFRACTION,"3,5",667,2018-06-13,active_or_active_like,active?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993540/,"Co-crystallisation with active-state stabilizing nanobody, This confirms that the nanobody does not deform US28 but merely selects a subset of pre-existing, stable, active-like conformations.(c)",0
5WF5,5WF5_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Agonist bound human A2a adenosine receptor with D52N mutation at 2.60 A resolution,X-RAY DIFFRACTION,"2,6",504,2018-02-21,active-like,active-like,https://www.ncbi.nlm.nih.gov/pubmed/?term=29395784,Co-crystallisation with agonist,Endolysin
5WF6,5WF6_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Agonist bound human A2a adenosine receptor with S91A mutation at 2.90 A resolution,X-RAY DIFFRACTION,"2,9",504,2018-02-21,active-like,active-like,https://www.ncbi.nlm.nih.gov/pubmed/?term=29395784,Co-crystallisation with agonist,Endolysin
5WIU,5WIU_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the human D4 Dopamine receptor in complex with Nemonapride,X-RAY DIFFRACTION,"1,96",422,2017-10-18,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856174/,"Co-crystallisation with antipsychotic drug nemonapride, Thus, the hydrogen bond between 7.35 and 6.55 potentiates DRD3 constitutive activity, while its absence in DRD4, together with the closer proximity of TM V and VI, may explain the more inactive DRD4/nemonapride structure(c)",Glycogen synthase
5WIV,5WIV_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the sodium-bound human D4 Dopamine receptor in complex with Nemonapride,X-RAY DIFFRACTION,"2,14",422,2017-10-18,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856174/,"Co-crystallisation with antipsychotic drug nemonapride, Thus, the hydrogen bond between 7.35 and 6.55 potentiates DRD3 constitutive activity, while its absence in DRD4, together with the closer proximity of TM V and VI, may explain the more inactive DRD4/nemonapride structure(c)",0
5WQC,5WQC_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human orexin 2 receptor bound to the selective antagonist EMPA determined by the synchrotron light source at SPring-8.,X-RAY DIFFRACTION,"1,96",560,2017-11-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29225076,"Co-crystallisation with antagonist EMPA, ",Glycogen synthase
5WS3,5WS3_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structures of human orexin 2 receptor bound to the selective antagonist EMPA determined by serial femtosecond crystallography at SACLA,X-RAY DIFFRACTION,"2,3",560,2017-12-13,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29225076,"Co-crystallisation with antagonist EMPA, ",0
5X33,5X33_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Leukotriene B4 receptor BLT1 in complex with BIIL260,X-RAY DIFFRACTION,"3,7",523,2018-01-03,inactive,inactive,https://sci-hub.tw/10.1038/nchembio.2547,"Co-crystallisation with allosteric modulator BIIL260, As a consequence
of these interactions, the benzamidine moiety of BIIL260 ejects the
sodium ion–centered water cluster and instead stabilizes the inactive state of BLT1. Therefore, we concluded that BIIL260 serves as
an inverse agonist for BLT1 (c)",0
5X7D,5X7D_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of beta2 adrenoceptor bound to carazolol and an intracellular allosteric antagonist,X-RAY DIFFRACTION,"2,7",500,2017-08-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818265/,"Co-crystallisation with allosteric modulator Cmpd-15, Cmpd-15PA stabilizes TM6 in the inactive state through direct polar interactions with side chain of Thr2746.36 and non-polar interactions with side chains of Ala2716.33 and Leu2756.37(c)",Soluble cytochrome b562
5X93,5X93_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Human endothelin receptor type-B in complex with antagonist K-8794,X-RAY DIFFRACTION,"2,2",464,2017-08-16,inactive,inactive,https://sci-hub.tw/10.1038/nsmb.3450,"Co-crystallisation with antagonist K-8794,  The overall structure of the bosentanbound ETB-Y4-mT4L is similar to those of the K8794-bound and the
ligand-free, inactive conformations (r.m.s. deviation = 1.36 and 1.35 Å,
respectively) (Fig. 1b), except for slight structural differences in ICL2,
which probably reflect its innate flexibility(c)",T4-Lysozyme
5XJM,5XJM_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Complex structure of angiotensin II type 2 receptor with Fab,X-RAY DIFFRACTION,"3,2",862,2018-07-11,active,active,https://sci-hub.tw/10.1038/s41594-018-0079-8,"Co-crystallisation with agonist s-AngII, This should also be the
reason why s-AngII shows agonistic activity to AT2R and why the
structure of the s-AngII–AT2R complex indicates that it is in the
active conformation.(c)",Rubredoxin
5XPR,5XPR_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Human endothelin receptor type-B in complex with antagonist bosentan,X-RAY DIFFRACTION,"3,6",464,2017-08-16,inactive,inactive,https://sci-hub.tw/10.1038/nsmb.3450,"Co-crystallisation with antagonist bosentan,  The overall structure of the bosentanbound ETB-Y4-mT4L is similar to those of the K8794-bound and the
ligand-free, inactive conformations (r.m.s. deviation = 1.36 and 1.35 Å,
respectively) (Fig. 1b), except for slight structural differences in ICL2,
which probably reflect its innate flexibility(c)",Endolysin
5XR8,5XR8_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human CB1 in complex with agonist AM841,X-RAY DIFFRACTION,"2,95",438,2017-07-12,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793864/,"Co crystallisation with agonist AM841, cAMP assay",Flavodoxin
5XRA,5XRA_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human CB1 in complex with agonist AM11542,X-RAY DIFFRACTION,"2,8",438,2017-07-12,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793864/,"Co crystallisation with agonist AM11542, cAMP assay",0
5XSZ,5XSZ_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of zebrafish lysophosphatidic acid receptor LPA6,X-RAY DIFFRACTION,"3,2",477,2017-08-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=28792932,"G-protein coupling assay, . Accordingly, the
conserved D(E)R3.50Y and NP7.50XXY motifs, which undergo structural rearrangements during the receptor activation, adopt inactive-like
conformations in the LPA6 structure6,8
 (Extended Data Figs 3c, 4b).
Thus, the present LPA6 structure probably represents the inactive state(c)",0
5YC8,5YC8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with NMS (Hg-derivative),X-RAY DIFFRACTION,"2,5",421,2018-11-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30420692,Co-crystallisation with inverse agonist NMS,Endolysin
5YHL,5YHL_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human prostaglandin E receptor EP4 in complex with Fab and an antagonist Br-derivative,X-RAY DIFFRACTION,"4,2",821,2018-12-05,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30510193,Co-crystallisation with inactive-atate atabilazing antibody FAb001,Fab
5YWY,5YWY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human prostaglandin E receptor EP4 in complex with Fab and ONO-AE3-208,X-RAY DIFFRACTION,"3,2",821,2018-12-05,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30510193,Co-crystallisation with inactive-atate atabilazing antibody FAb002,Soluble cytochrome b562
5ZBH,5ZBH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The Crystal Structure of Human Neuropeptide Y Y1 Receptor with BMS-193885,X-RAY DIFFRACTION,3,527,2018-04-25,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920736/,"Co-crystallisation with the antagonist BMS193885, The Y1R–UR-MK299 and Y1R–BMS-193885 complexes are structurally similar with Cα root-mean-square deviation (r.m.s.d.) of 0.75 Å within the helical bundle, and both exhibit inactive conformations with helix VI adopting a similar inward conformation as that in the other inactive GPCR structures.(c)",T4-Lysozyme
5ZBQ,5ZBQ_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The Crystal Structure of human neuropeptide Y Y1 receptor with UR-MK299,X-RAY DIFFRACTION,"2,7",525,2018-04-25,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920736/,"Co-crystallisation with the antagonist MK299, The Y1R–UR-MK299 and Y1R–BMS-193885 complexes are structurally similar with Cα root-mean-square deviation (r.m.s.d.) of 0.75 Å within the helical bundle, and both exhibit inactive conformations with helix VI adopting a similar inward conformation as that in the other inactive GPCR structures.(c)",T4-Lysozyme
5ZHP,5ZHP_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,M3 muscarinic acetylcholine receptor in complex with a selective antagonist,X-RAY DIFFRACTION,"3,1",836,2018-11-28,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255194/,"Co-crystallisation with structure-base designed antaonist, betta arrestin recruitment assay Ligand Design.
MR ligand design was guided by structures of the M2R inactive-state crystal structure [Protein Data Bank (PDB) ID code 3UON] bound to the antagonist QNB and the M3R inactive structure (PDB ID code 4DAJ) bound to the inverse agonist tiotropium.(c)",Fab
5ZK3,5ZK3_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with QNB,X-RAY DIFFRACTION,"2,6",421,2018-11-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30420692,"Co-crystallisation with antagonist ( It should be noted that these distances are not used for
measuring the receptor activation since we are simulating the conformational ensemble just
around the inactive states of the M2 receptor in this study)",Redesigned apo-cytochrome b562
5ZK8,5ZK8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of M2 muscarinic acetylcholine receptor bound with NMS,X-RAY DIFFRACTION,3,421,2018-11-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30420692,"Co-crystallisation with antagonist ( It should be noted that these distances are not used for
measuring the receptor activation since we are simulating the conformational ensemble just
around the inactive states of the M2 receptor in this study)",Apo-cytochrome b562
5ZKB,5ZKB_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with AF-DX 384,X-RAY DIFFRACTION,"2,95",421,2018-11-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30420692,"Co-crystallisation with antagonist ( It should be noted that these distances are not used for
measuring the receptor activation since we are simulating the conformational ensemble just
around the inactive states of the M2 receptor in this study)",Redesigned apo-cytochrome b562
5ZKC,5ZKC_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with NMS,X-RAY DIFFRACTION,"2,3",421,2018-11-21,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30420692,"Co-crystallisation with antagonist ( It should be noted that these distances are not used for
measuring the receptor activation since we are simulating the conformational ensemble just
around the inactive states of the M2 receptor in this study)",Apo-cytochrome b562
5ZKP,5ZKP_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human platelet-activating factor receptor in complex with SR 27417,X-RAY DIFFRACTION,"2,81",466,2018-06-20,active_or_active_like,"active, active-like(?)",https://www.ncbi.nlm.nih.gov/pubmed/?term=29808000,"Co crystallisation with SR 27417, facilitate G-protein signalling",Fab
5ZKQ,5ZKQ_b_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human platelet-activating factor receptor in complex with ABT-491,X-RAY DIFFRACTION,"2,9",876,2018-06-20,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=29808000,Co-crystallisation with iverse agonist,Flavodoxin
5ZTY,5ZTY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of the Human Cannabinoid Receptor CB2 in complex with a rationally designed antagonist AM10257,X-RAY DIFFRACTION,"2,8",500,2019-01-30,active_or_active_like,active-like???,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713262/,Co-crystallisation with antagonist AM10257??,scFv16
6A93,6A93_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of 5-HT2AR in complex with risperidone,X-RAY DIFFRACTION,3,752,2019-02-13,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30723326,"CO-crystallisation with antagonist risperidone, The close contacts between the ligands and Ile1633.40x40 and
Phe3326.44x44 in the PIF motif, and the toggle switch Trp3366.48x48, are likely to block the rearrangements of these residues on activation
and contribute to effectively stabilizing the structure in the inactive state(c), GPCR activation (percentage of AP-TGFα release) - state determinition",Endolysin
6A94,6A94_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of 5-HT2AR in complex with zotepine,X-RAY DIFFRACTION,"2,9",752,2019-02-13,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30723326,"CO-crystallisation with antagonist zotepine, The close contacts between the ligands and Ile1633.40x40 and
Phe3326.44x44 in the PIF motif, and the toggle switch Trp3366.48x48, are likely to block the rearrangements of these residues on activation
and contribute to effectively stabilizing the structure in the inactive state(c).GPCR activation (percentage of AP-TGFα release) - state determinition",Soluble cytochrome b562
6AK3,6AK3_b_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human prostaglandin E receptor EP3 bound to prostaglandin E2,X-RAY DIFFRACTION,"2,9",836,2018-12-05,active-like,active-like?,https://sci-hub.tw/10.1038/nature19319,"Co-crystallisation with agonist PGE2, TMs 5 and 6 are displaced outward by 2.8Å and 7.5Å, respectively, and TM7 is rearranged inward by 5.3Å (Fig. 3b), indicating that EP3–PGE2 is in an active-like state",Endolysin chimera
6AKX,6AKX_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The Crystal structure of Human Chemokine Receptor CCR5 in complex with compound 21,X-RAY DIFFRACTION,"2,8",762,2018-10-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30234300,Co-crystallisaton with antagonist + cell cultture tests as maraviroc,Endolysin
6AKY,6AKY_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,The Crystal structure of Human Chemokine Receptor CCR5 in complex with compound 34,X-RAY DIFFRACTION,"2,8",381,2018-10-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30234300,Co-crystallisaton with antagonist + cell cultture tests as maraviroc,Rubredoxin
6AQF,6AQF_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of A2AAR-BRIL in complex with the antagonist ZM241385 produced from Pichia pastoris,X-RAY DIFFRACTION,"2,51",432,2018-01-10,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766378/,"Co-crystallisation with antagonist ZM241385 + BRIL construct, To obtain information on the allosteric switch at Asp522.50, we compared corresponding NMR data of A2AAR and A2AAR[D52N], where the allosteric center is known to be inactive (Massink et al., 2014).(c)",Soluble cytochrome b562
6B73,6B73_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor,X-RAY DIFFRACTION,"3,1",1104,2018-01-17,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802374/,Co-crystallisation with the potent epoxymorphinan opioid agonist MP1104 and an active state stabilizing nanobody(c),T4-Lysozyme
6BQG,6BQG_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of 5-HT2C in complex with ergotamine,X-RAY DIFFRACTION,3,452,2018-02-14,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309861/,"Co-crystallisation with agonist ergotamine, comp with B2AR",0
6BQH,6BQH_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of 5-HT2C in complex with ritanserin,X-RAY DIFFRACTION,"2,7",452,2018-02-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309861/,"Co-crystallisation with inverse agonist ritanserin, comp with B2AR",Soluble cytochrome b562
6C1Q,6C1Q_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist NDT9513727,X-RAY DIFFRACTION,"2,9",429,2018-05-30,inactive,inactive,https://sci-hub.tw/10.1038/s41594-018-0067-z,"Co-crystallisation with peptide antagonist PMX53 and non-peptise antagonist avacopan, Thus, non-peptide C5aR antagonists may
stabilize I1243.40, P2145.50 and F2516.44 in the inactive state to prevent
the movement of TM5 and TM6 that is required for receptor activation to achieve antagonism. (c)",Soluble cytochrome b562
6C1R,6C1R_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist avacopan,X-RAY DIFFRACTION,"2,2",429,2018-05-30,inactive,inactive,https://sci-hub.tw/10.1038/s41594-018-0067-z,"Co-crystallisation with peptide antagonist PMX53 and non-peptise antagonist NDT951727, Thus, non-peptide C5aR antagonists may
stabilize I1243.40, P2145.50 and F2516.44 in the inactive state to prevent
the movement of TM5 and TM6 that is required for receptor activation to achieve antagonism. (c)",0
6CM4,6CM4_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structure of the D2 Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone,X-RAY DIFFRACTION,"2,87",430,2018-03-14,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843546/,"Co-crystallisation with inverse agonist risperidone, Like most antipsychotics, risperidone is a DRD2 inverse agonist22, and the DRD2/risperidone complex appropriately reflects an inactive state conformation.(c)",0
6D26,6D26_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the prostaglandin D2 receptor CRTH2 with fevipiprant,X-RAY DIFFRACTION,"2,8",470,2018-10-03,inactive,inactive(?),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223628/,Co-crystallisation with antagonist,0
6D27,6D27_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the prostaglandin D2 receptor CRTH2 with CAY10471,X-RAY DIFFRACTION,"2,74",470,2018-10-03,inactive,inactive(?),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223628/,Co-crystallisation with antagonist,Endolysin
6D9H,6D9H_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Cryo-EM structure of the human adenosine A1 receptor-Gi2-protein complex bound to its endogenous agonist,ELECTRON MICROSCOPY,"3,6",1165,2018-06-20,active,active,https://sci-hub.tw/10.1038/s41586-018-0236-6,"Co-crystallisation with Gi protein, This
active A1R structure provides molecular insights into receptor and G-protein selectivity(c)",0
6DDE,6DDE_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Mu Opioid Receptor-Gi Protein Complex,ELECTRON MICROSCOPY,"3,5",1389,2018-06-13,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317904/,Co-crystallisation with agonist DAMGO and active state stabilizing nanobody,Endolysin
6DDF,6DDF_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Mu Opioid Receptor-Gi Protein Complex,ELECTRON MICROSCOPY,"3,5",1130,2018-06-13,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317904/,Co-crystallisation with agonist DAMGO,0
6DO1,6DO1_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8,X-RAY DIFFRACTION,"2,9",1370,2019-01-30,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367718/,"Co-crystallisation with stabilizing nanobody, By stabilizing the receptor with a single-domain antibody fragment (“nanobody”) discovered using a synthetic yeast-displayed library, we determined the crystal structure of active-state human AT1R bound to an AngII analog with partial agonist activity(c)",Soluble cytochrome b562
6DRX,6DRX_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor,X-RAY DIFFRACTION,"3,1",410,2018-08-29,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237183/#R18,,Soluble cytochrome b562
6DRY,6DRY_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor,X-RAY DIFFRACTION,"2,92",411,2018-08-29,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237183/#R19,,Soluble cytochrome b562
6DRZ,6DRZ_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor,X-RAY DIFFRACTION,"3,1",411,2018-08-29,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237183/#R20,,Soluble cytochrome b562
6DS0,6DS0_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor,X-RAY DIFFRACTION,"3,19",410,2018-08-29,active_like,partially active?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237183/#R21,,Receptor activity-modifying protein 1
6E59,6E59_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human NK1 tachykinin receptor,X-RAY DIFFRACTION,"3,4",542,2018-12-12,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310836/pdf/pnas.201812717.pdf,"Co-crystallisation with antagonist(L760735).These efforts will build
on the inactive state structure reported here(c)",0
6E67,6E67_b_Active_loop_optimized_reg.pdb,added structures,1 week ago,Structure of beta2 adrenergic receptor fused to a Gs peptide,X-RAY DIFFRACTION,"3,7",1062,2019-06-05,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991123/,"Co-crystallisation with Gs protein, Thus, β2AR is stabilized in an active conformation in β2AR-T4L-GsCT-CC construct.(c)",0
6G79,6G79_s_Active_loop_optimized_reg.pdb,added structures,1 week ago,Coupling specificity of heterotrimeric Go to the serotonin 5-HT1B receptor,ELECTRON MICROSCOPY,"3,78",999,2018-06-20,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027989/,"Co-crystallisation with G0 protrin, The overall conformation of 5-HT1BR in the cryo-EM structure is consistent with the receptor being in a fully active state(c)",Soluble cytochrome b562  Fab
6GDG,6GDG_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Cryo-EM structure of the adenosine A2A receptor bound to a miniGs heterotrimer,ELECTRON MICROSCOPY,"4,11",1293,2018-05-16,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962338/,"Co-ctystallisation with engeneered G protein, The extracellular half of A2AR does not undergo any major structural changes in the transition from the active intermediate to the mini-GS coupled active state, with the volume of the binding pocket remaining constant and the interactions to NECA being identical (Carpenter et al., 2016).(c)",Cytochrome b562
6GPS,6GPS_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,CRYSTAL STRUCTURE OF CCR2A IN COMPLEX WITH MK-0812,X-RAY DIFFRACTION,"3,3",429,2019-01-02,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30581043,"CO-crystallisation with antagonist.  The inactive chemokine receptor structural
signature, previously determined for the CCR5-maraviroc complex and the ternary CCR2B complex, is also adopted in our
structures.(c)",Thioredoxin 1
6GPX,6GPX_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,CRYSTAL STRUCTURE OF CCR2A IN COMPLEX WITH MK-0812,X-RAY DIFFRACTION,"2,7",698,2019-01-02,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30581043,"CO-crystallisation with antagonist.  The inactive chemokine receptor structural
signature, previously determined for the CCR5-maraviroc complex and the ternary CCR2B complex, is also adopted in our
structures.(c)",Rubredoxin
6GT3,6GT3_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of the A2A-StaR2-bRIL562 in complex with AZD4635 at 2.0A resolution,X-RAY DIFFRACTION,2,433,2019-06-26,inactive,inactive?,https://soseiheptares.com/uploads/publications/AZD4635%20AACR%202017%20Pharmacology%20Poster%20-%20PDF.pdf,"Co-ceystallisation with antagonist AZD4635, A2A-StaR2-bRIL562",0
6H7J,6H7J_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST ISOPRENALINE AND NANOBODY Nb80,X-RAY DIFFRACTION,"2,8",1074,2018-10-17,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586556/,nanobody stabilised gpcr bound to the agonists(full),Thioredoxin 1
6H7L,6H7L_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST DOBUTAMINE AND NANOBODY Nb6B9,X-RAY DIFFRACTION,"2,7",1074,2018-10-17,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586556/,nanobody stabilised gpcr bound to the agonists(partial),Thioredoxin 1
6H7M,6H7M_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST SALBUTAMOL AND NANOBODY Nb6B9,X-RAY DIFFRACTION,"2,76",1074,2018-10-17,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586556/,nanobody stabilised gpcr bound to the agonists(partial),Thioredoxin 1
6H7N,6H7N_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST XAMOTEROL AND NANOBODY Nb6B9,X-RAY DIFFRACTION,"2,5",1074,2018-10-17,active,active,??,nanobody stabilised gpcr bound to the agonists??,Rubredoxin
6H7O,6H7O_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND WEAK PARTIAL AGONIST CYANOPINDOLOL AND NANOBODY Nb6B9,X-RAY DIFFRACTION,"2,8",1074,2018-10-17,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586556/,nanobody stabilised gpcr bound to the agonists(weak),Thioredoxin 1
6HLL,6HLL_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,"Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist CP-99,994",X-RAY DIFFRACTION,"3,27",520,2019-01-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318301/,"gpcr + antagonist.Taken together, the NK1R structures in complex with different antagonists capture the inactive receptor conformation.(c)",GIgA glycogen synthase
6HLO,6HLO_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist Aprepitant,X-RAY DIFFRACTION,"2,4",520,2019-01-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318301/,"gpcr + antagonist.Taken together, the NK1R structures in complex with different antagonists capture the inactive receptor conformation.(c)",GIgA glycogen synthase
6HLP,6HLP_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist Netupitant,X-RAY DIFFRACTION,"2,2",520,2019-01-16,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318301/,"gpcr + antagonist.Taken together, the NK1R structures in complex with different antagonists capture the inactive receptor conformation.(c)",0
6IBL,6IBL_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST FORMOTEROL AND NANOBODY Nb80,X-RAY DIFFRACTION,"2,7",1074,2019-01-09,active,?,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115876/,This implied that β1AR6P coupled to arrestin was in an active state—as has been also observed for other GPCRs15—and that arrestin coupling and G-protein coupling have different effects on the orthosteric binding site.,GIgA glycogen synthase
6IGK,6IGK_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of human ETB receptor in complex with Endothelin-3,X-RAY DIFFRACTION,2,519,2018-11-21,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226434/,"gpcr bound to the full agonist, betta arrestin assay, TGFα shedding assay",Apo-cytochrome b562
6IGL,6IGL_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal Structure of human ETB receptor in complex with IRL1620,X-RAY DIFFRACTION,"2,7",513,2018-11-21,partially_active,partially active??,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226434/,"gpcr bound to the partial agonist, betta arrestin assay, TGFα shedding assay",Endolysin
6IIU,6IIU_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human thromboxane A2 receptor bound to ramatroban,X-RAY DIFFRACTION,"2,5",484,2018-12-19,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30510189,Co-crystallisation with antagonist ramatroban,Soluble cytochrome b562  Rubredoxin
6IIV,6IIV_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human thromboxane A2 receptor bound to daltroban,X-RAY DIFFRACTION,3,484,2018-12-19,inactive,inactive,https://www.ncbi.nlm.nih.gov/pubmed/?term=30510189,Co-crystallisation with antagonist daltroban,Rubredoxin
6J20,6J20_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human NK1 substance P receptor,X-RAY DIFFRACTION,"2,7",441,2019-03-06,inactive,inactive? see cAMP accumulation assay,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367319/,"Co-crystallisation with antagonist aprepitant. Since these structural differences were not likely induced by the fusion partner differences between the two structures22, our data suggest that the NK1R–aprepitant structure is in an inactive state.(c)",Endolysin
6J21,6J21_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of the human NK1 substance P receptor,X-RAY DIFFRACTION,"3,2",441,2019-03-06,inactive,inactive? see cAMP accumulation assay,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367319/,"Co-crystallisation with antagonist aprepitant. Since these structural differences were not likely induced by the fusion partner differences between the two structures22, our data suggest that the NK1R–aprepitant structure is in an inactive state.(c)",0
6M9T,6M9T_a_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of EP3 receptor bound to misoprostol-FA,X-RAY DIFFRACTION,"2,5",537,2018-12-05,active-like,active-like,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289721/,"Co-crystallisation with agonist, structural comparison with the cannabinoid receptor Cb1",GlgA glycogen synthase
6ME2,6ME2_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT1 in complex with ramelteon,X-RAY DIFFRACTION,"2,8",503,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696938/,"mutations, which lock the rec in inact conf D732.50N, L95ECL1F, G1043.29A, F1163.41W, N1243.49D, C1273.52L, W2516.48F, A2927.50P, N2998.4",GIgA glycogen synthase
6ME3,6ME3_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT1 in complex with 2-phenylmelatonin,X-RAY DIFFRACTION,"2,9",503,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696938/,"mutations, which lock the rec in inact conf D732.50N, L95ECL1F, G1043.29A, F1163.41W, N1243.49D, C1273.52L, W2516.48F, A2927.50P, N2998.5",GlgA glycogen synthase
6ME4,6ME4_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT1 in complex with 2-iodomelatonin,X-RAY DIFFRACTION,"3,2",503,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696938/,"mutations, which lock the rec in inact conf D732.50N, L95ECL1F, G1043.29A, F1163.41W, N1243.49D, C1273.52L, W2516.48F, A2927.50P, N2998.6",GIgA glycogen synthase
6ME5,6ME5_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT1 in complex with agomelatine,X-RAY DIFFRACTION,"3,2",503,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696938/,"mutations, which lock the rec in inact conf D732.50N, L95ECL1F, G1043.29A, F1163.41W, N1243.49D, C1273.52L, W2516.48F, A2927.50P, N2998.7",Soluble cytochrome b562
6ME6,6ME6_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT2 in complex with 2-phenylmelatonin,X-RAY DIFFRACTION,"2,8",920,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589158/,"mutations D862.50N9, L108ECL1F, F1293.41W10, N1373.49D, C1403.52L, W2646.48F, A3057.50P, and N3128.47D",GlgA glycogen synthase
6ME7,6ME7_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin,X-RAY DIFFRACTION,"3,2",920,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589158/,"mutations D862.50N9, L108ECL1F, F1293.41W10, N1373.49D, C1403.52L, W2646.48F, A3057.50P, and N3128.47D",Soluble cytochrome b562  Rubredoxin
6ME8,6ME8_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT2 (N86D) in complex with 2-phenylmelatonin,X-RAY DIFFRACTION,"3,1",920,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589158/,"mutations D862.50N9, L108ECL1F, F1293.41W10, N1373.49D, C1403.52L, W2646.48F, A3057.50P, and N3128.47D",Soluble cytochrome b562  Rubredoxin
6ME9,6ME9_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,XFEL crystal structure of human melatonin receptor MT2 in complex with ramelteon,X-RAY DIFFRACTION,"3,3",920,2019-04-24,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589158/,"mutations D862.50N9, L108ECL1F, F1293.41W10, N1373.49D, C1403.52L, W2646.48F, A3057.50P, and N3128.47D",Soluble cytochrome b562  Rubredoxin
6MEO,6MEO_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structural basis of coreceptor recognition by HIV-1 envelope spike,ELECTRON MICROSCOPY,"3,9",950,2018-12-12,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391877/,"Comparison of the structures of the CCR5-maraviroc and CCR5-gp120 complexes indicates that the parts of all TM helices near the intracellular side, including TM6,  indicating that the gp120-bound CCR5 also adopts an inactive conformation (chem bind assay)",T-cell surface glycoprotein CD4
6MET,6MET_b_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,Structural basis of coreceptor recognition by HIV-1 envelope spike,ELECTRON MICROSCOPY,"4,5",1137,2018-12-12,inactive,inactive,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391877/,"Comparison of the structures of the CCR5-maraviroc and CCR5-gp120 complexes indicates that the parts of all TM helices near the intracellular side, including TM6,  indicating that the gp120-bound CCR5 also adopts an inactive conformation (chem bind assay)",Soluble cytochrome b562  Rubredoxin
6MH8,6MH8_a_Inactive_loop_optimized_reg.pdb,added structures,1 week ago,High-viscosity injector-based Pink Beam Serial Crystallography of Micro-crystals at a Synchrotron Radiation Source,X-RAY DIFFRACTION,"4,2",447,2019-04-24,inactive,??,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503920/,"Microcrystals of A2AAR and PK were prepared as previously described (Martin-Garcia et al., 2017 ▸).",0
6MXT,6MXT_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71,X-RAY DIFFRACTION,"2,96",594,2018-11-14,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197491/,active-state stabilizing nanobody.,GlgA glycogen synthase
6N48,6N48_a_Active_loop_optimized_reg.pdb,added structures,1 week ago,"Structure of beta2 adrenergic receptor bound to BI167107, Nanobody 6B9, and a positive allosteric modulator",X-RAY DIFFRACTION,"3,2",589,2019-06-26,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705129/,nanobody 6B9 (Nb6B9) to stabilize the active-state of β2AR,Soluble cytochrome bb562
6N4B,6N4B_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Cannabinoid Receptor 1-G Protein Complex,ELECTRON MICROSCOPY,3,1523,2019-01-30,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461403/,interacts with SPICE,Soluble cytochrome b562
6OIJ,6OIJ_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Muscarinic acetylcholine receptor 1-G11 protein complex,ELECTRON MICROSCOPY,"3,3",1388,2019-05-08,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034192/,"To extend our understanding of coupling specificity to GPCR-Gq/11 complexes, we used single-particle cryo-EM to obtain the structures of active M1R and M2R engaged with heterotrimeric G11 and GoA proteins, two distinct G proteins belonging to the Gq/11 and Gi/o family, respectively.  M1R/G11iN/scFv16",Endolysin
6OIK,6OIK_r_Active_loop_optimized_reg.pdb,added structures,1 week ago,Muscarinic acetylcholine receptor 2-Go complex,ELECTRON MICROSCOPY,"3,6",1379,2019-05-08,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034192/,M2R/GoAiN/scFv16,0
6OS9,6OS9_r_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,human Neurotensin Receptor 1 (hNTSR1) - Gi1 Protein Complex in canonical conformation (C state),ELECTRON MICROSCOPY,3,1469,2019-07-10,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065593/,,0
6OSA,6OSA_r_Intermediate_loop_optimized_reg.pdb,added structures,1 week ago,human Neurotensin Receptor 1 (hNTSR1) - Gi1 Protein Complex in non-canonical conformation (NC state),ELECTRON MICROSCOPY,3,1210,2019-07-10,intermadiate,intermadiate,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065593/,,Endolysin
6VMS,6VMS,added structures,2 week ago,Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane,ELECTRON MICROSCOPY,"3,8",​,2020-06-17,active,active,https://www.nature.com/articles/s41586-020-2379-5.pdf,"agonist-bound activated DRD2–Gi complex,  The
structure of hDRD2EM in the complex is in close agreement with our computationally designed active-state conformation (Fig. 1d) (Cα root mean
squared deviation: 2.1 Å overall and 1 Å for the transmembrane helices)(c)",0
7C7Q,,,,Cryo-EM structure of the baclofen/BHFF-bound human GABA(B) receptor in active state,ELECTRON MICROSCOPY,3,,2020-07-01,active,active,https://www.nature.com/articles/s41422-020-0350-5.pdf,"Here we present cryo-EM structures of full-length human heterodimeric GABAB receptor in the antagonist-bound inactive state and in the agonist/PAMbound active state complexed with heterotrimeric Gi1 protein, shedding lights on class C GPCR activation and providing a rational template for allosteric modulator design targeting the dimeric interface of GABAB receptor",
7C7S,,,,Cryo-EM structure of the CGP54626-bound human GABA(B) receptor in inactive state.,ELECTRON MICROSCOPY,"2,9",,2020-07-01,inactive,inactive,https://www.nature.com/articles/s41422-020-0350-5.pdf,"Here we present cryo-EM structures of full-length human heterodimeric GABAB receptor in the antagonist-bound inactive state and in the agonist/PAMbound active state complexed with heterotrimeric Gi1 protein, shedding lights on class C GPCR activation and providing a rational template for allosteric modulator design targeting the dimeric interface of GABAB receptor",
6U1N,,,,GPCR-Beta arrestin structure in lipid bilayer,ELECTRON MICROSCOPY,4,,2020-02-26,active,active,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367492/,"Co-crystallisation with betta-arrestin., This map showed relatively lower resolution in the 7TM region, including poor density of the highly mobile
transmembrane helix 1 (TM1), but nevertheless enabled a confident
comparison with M2R active-state structures . this suggests that the interaction between the C-edge and the membrane stabilizes the active conformation of βarr1.",
6UP7,,,,neurotensin receptor and arrestin2 complex,ELECTRON MICROSCOPY,"4,2",,2020-02-26,active,active,https://www.nature.com/articles/s41586-020-1953-1.pdf,"both TM6 and TM5 in the NTSR1–βarr1(ΔCT) structure move away from the core by 10.9 Å and 5.0 Å, respectively (Fig. 2b), adopting an active conformation similar to that seen in the C-state of the Gi -coupled NTSR1 structure (discussed above)9 , with a root-mean-square deviation of 0.67 Å",
6LFO,,,,,,,,,active,active,https://www.nature.com/articles/s41586-020-2492-5_reference.pdf,"The overall structures of dimeric and monomeric CXCL8-bound CXCR2-Gi complexes are almost identical and their Cα atoms’ root mean square deviation (RMSD) is only 0.49 Å excluding CXCL8 (Extended Data Fig. 4). Since the density for CXCL8 is clearer in CXCR2-CXCL8 (dimer)-Gi -scFv16, the following analysis is focused on the dimeric CXCL8-bound complex structure. Compared with the antagonist 00767013-bound structure (Fig. 1b), the extracellular region of CXCL8-bound CXCR2 is more compact with the extracellular portion of TM5 moving inwards by about 6.3 Å",
6LFM,,,,,,,,,active,active,https://www.nature.com/articles/s41586-020-2492-5_reference.pdf,"The overall structures of dimeric and monomeric CXCL8-bound CXCR2-Gi complexes are almost identical and their Cα atoms’ root mean square deviation (RMSD) is only 0.49 Å excluding CXCL8 (Extended Data Fig. 4). Since the density for CXCL8 is clearer in CXCR2-CXCL8 (dimer)-Gi -scFv16, the following analysis is focused on the dimeric CXCL8-bound complex structure. Compared with the antagonist 00767013-bound structure (Fig. 1b), the extracellular region of CXCL8-bound CXCR2 is more compact with the extracellular portion of TM5 moving inwards by about 6.3 Å",
6LFL,,,,,,,,,inactive,inactive,https://www.nature.com/articles/s41586-020-2492-5_reference.pdf,"The overall structures of dimeric and monomeric CXCL8-bound CXCR2-Gi complexes are almost identical and their Cα atoms’ root mean square deviation (RMSD) is only 0.49 Å excluding CXCL8 (Extended Data Fig. 4). Since the density for CXCL8 is clearer in CXCR2-CXCL8 (dimer)-Gi -scFv16, the following analysis is focused on the dimeric CXCL8-bound complex structure. Compared with the antagonist 00767013-bound structure (Fig. 1b), the extracellular region of CXCL8-bound CXCR2 is more compact with the extracellular portion of TM5 moving inwards by about 6.3 Å",
6TPK,,,,Crystal structure of oxytocin receptor in complex with antagoist,,,,,inactive,inactive,https://advances.sciencemag.org/content/6/29/eabb5419.full,"Co-crystallisation with antagonist retosiban, However, these extracellular conformational differences are not transferred to the intracellular side of the helical bundle since, on this part of the receptor, the helical conformations coincide with those of previously determined inactive peptidergic GPCR structures, consistent with the expectation that the OTR structure in complex with the antagonist retosiban is captured in the inactive state.(c)",
7BR3,GnRH1R,added structures,-,Structure of human gonadotropin-releasing hormone receptor,X-RAY DIFFRACTION,2.79,470,2020-10-07,inactive,inactive,https://www.nature.com/articles/s41467-020-19109-w," In summary, the GnRH1R crystallized in complex with the antagonist drug elagolix represents an inactive conformation with respect to G protein coupling.",
6TPK,OTR,added structures,-,Crystal structure of the human oxytocin receptor,X-RAY DIFFRACTION,3.20,461,2020-08-05,inactive,inactive,https://advances.sciencemag.org/content/6/29/eabb5419.full,"However, these extracellular conformational differences are not transferred to the intracellular side of the helical bundle since, on this part of the receptor, the helical conformations coincide with those of previously determined inactive peptidergic GPCR structures, consistent with the expectation that the OTR structure in complex with the antagonist retosiban is captured in the inactive state.",
6VN7,VIP1 receptor-G protein complex,added structures,-,Cryo-EM structure of an activated VIP1 receptor-G protein complex,ELECTRON MICROSCOPY,3.20,1052,2020-09-02,active,active,https://www.nature.com/articles/s41467-020-17933-8," Indeed, mutations that disrupt this polar network in VIP1R have resulted in the constitutively active receptor",
6KO5,Ghrelin receptor,added structures,-,Complex structure of Ghrelin receptor with Fab,X-RAY DIFFRACTION,3.30,835,2020-08-12,inactive,inactive,https://www.nature.com/articles/s41467-020-17554-1,"The structure superimposed well with that of the inactive OX2 orexin receptor (PDB ID: 4S0V)19, with a root-mean-squared deviation of 0.819 Å. Thus, our structure of the ghrelin receptor probably represents the inactive state",